北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
作者: Zhou, Dao-bin1; Yu, Li2; Du, Xin3; Jin, Jie4; Cai, Zhen4; Chen, Fangping5; Ke, Xiaoyan6; Li, Xiao7; Wu, Depei8; Meng, Fanyi9; Ai, Huisheng10; Zhang, Jingshan11; DeMarco, Dena11; Chen, Nianhang11; Mei, Jay11; Wang, Jianmin12; Hou, Jian13
关键词: Chinese ; Multiple Myeloma ; Relapsed/Refractory ; Renal Insufficiency ; Lenalidomide
刊名: INTERNATIONAL JOURNAL OF HEMATOLOGY
发表日期: 2015-06-01
DOI: 10.1007/s12185-015-1771-7
卷: 101, 期:6, 页:569-577
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: FAILURE ; PHARMACOKINETICS ; REVERSIBILITY ; PATHOGENESIS ; AGENTS ; IMPACT
英文摘要:

Lower starting doses of lenalidomide (LEN) are recommended for patients with renal impairment (RI). In the present study, we conducted a subgroup analysis of the MM-021 registration trial to investigate the efficacy and safety of LEN plus low-dose dexamethasone (LoDEX) in Chinese patients with advanced relapsed or refractory multiple myeloma (RRMM) based on levels of RI. Patients received LEN+LoDEX until disease progression or discontinuation. Patients were divided according to RI: no/mild [creatinine clearance (CrCl) >= 60 mL/min, n = 131], moderate (CrCl >= 30 to <60 mL/min, n = 54), and severe (CrCl <30 mL/min, n = 14). LEN starting dose was 25 mg/day on days 1-21, adjusted for baseline renal function. Best overall response rate was 48 %; in patients with no/mild, moderate, or severe RI, response rates were 50, 42, and 42 %, respectively. Median progression-free survival and overall survival were longer in patients with no/mild RI (9.3 and 22.4 months, respectively) versus those with moderate (6.9 and 16.0 months) or severe RI(4.8 and 11.1 months). LEN+LoDEX was well tolerated, although incidences of grade 3-4 neutropenia, anemia, and thrombocytopenia were higher in patients with severe RI. In Chinese patients with advanced RRMM and RI, adjusting the starting dose of LEN according to renal function did not compromise the efficacy or safety of LEN+LoDEX.

语种: 英语
项目资助者: Celgene Corporation
WOS记录号: WOS:000357519200007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55468
Appears in Collections:北京大学第三临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Beijing Union Med Coll Hosp, Dept Hematol, Beijing 100730, Peoples R China
2.Chinese Peoples Liberat Army Gen Hosp, Hosp 301, Beijing 100853, Peoples R China
3.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
4.Zhejiang Univ, Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
5.Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
6.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
7.Shanghai 6th Hosp, Shanghai, Peoples R China
8.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
9.Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
10.307 PLA Hosp, Beijing, Peoples R China
11.Celgene Corp, Summit, NJ USA
12.Changhai Hosp, Shanghai, Peoples R China
13.Shanghai Changzheng Hosp, Shanghai, Peoples R China

Recommended Citation:
Zhou, Dao-bin,Yu, Li,Du, Xin,et al. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY,2015,101(6):569-577.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhou, Dao-bin]'s Articles
[Yu, Li]'s Articles
[Du, Xin]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhou, Dao-bin]‘s Articles
[Yu, Li]‘s Articles
[Du, Xin]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace